These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

563 related items for PubMed ID: 17091442

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Nebivolol, a vasodilating selective beta(1)-blocker, is a beta(3)-adrenoceptor agonist in the nonfailing transplanted human heart.
    Rozec B, Erfanian M, Laurent K, Trochu JN, Gauthier C.
    J Am Coll Cardiol; 2009 Apr 28; 53(17):1532-8. PubMed ID: 19389564
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Nebivolol: a third-generation beta-blocker for hypertension.
    Cheng JW.
    Clin Ther; 2009 Mar 28; 31(3):447-62. PubMed ID: 19393838
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Nebivolol: pharmacologic profile of an ultraselective, vasodilatory beta1-blocker.
    Prisant LM.
    J Clin Pharmacol; 2008 Feb 28; 48(2):225-39. PubMed ID: 18083889
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS).
    Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, Cohen-Solal A, Dumitrascu D, Ferrari R, Lechat P, Soler-Soler J, Tavazzi L, Spinarova L, Toman J, Böhm M, Anker SD, Thompson SG, Poole-Wilson PA, SENIORS Investigators.
    Eur Heart J; 2005 Feb 28; 26(3):215-25. PubMed ID: 15642700
    [Abstract] [Full Text] [Related]

  • 14. Nebivolol: haemodynamic effects and clinical significance of combined beta-blockade and nitric oxide release.
    Kamp O, Metra M, Bugatti S, Bettari L, Dei Cas A, Petrini N, Dei Cas L.
    Drugs; 2010 Feb 28; 70(1):41-56. PubMed ID: 20030424
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. ENOS is not activated by nebivolol in human failing myocardium.
    Brixius K, Song Q, Malick A, Boelck B, Addicks K, Bloch W, Mehlhorn U, Schwinger RH.
    Life Sci; 2006 Aug 22; 79(13):1234-41. PubMed ID: 16716362
    [Abstract] [Full Text] [Related]

  • 17. Nebivolol: the somewhat-different beta-adrenergic receptor blocker.
    Münzel T, Gori T.
    J Am Coll Cardiol; 2009 Oct 13; 54(16):1491-9. PubMed ID: 19815121
    [Abstract] [Full Text] [Related]

  • 18. [Advantages of vasodilating beta-blockers in congestive heart failure].
    Logeart D, Solal AC.
    Ann Cardiol Angeiol (Paris); 2010 Jun 13; 59(3):160-7. PubMed ID: 20620251
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.